Chronic kidney disease (CKD) is one of the fastest growing causes of death, projected to become the fifth global cause of death by 2040 and the second cause of death in countries with long life expectancy before the end of the century.1,2 While the increased risk of cardiovascular disease has received most attention,3 persons with CKD are at increased risk of death from non-cardiovascular causes and indeed the absolute increase in the risk of death from non-cardiovascular causes, including infection, is larger than for cardiovascular causes, especially in the elderly.4

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus disease 2019 (COVID-19), a condition of variable severity that may result in death. Initial reports of COVID-19 indicated that 20% of hospitalized patients had diabetes mellitus (DM), 15% hypertension and 15% had cardiovascular disease (CVD), but CKD was not mentioned5 and was not considered a risk factor for many months. It is now clearly established that CKD is the main risk factor for severe COVID-19.6 According to the Global Burden of Disease (GBD) collaboration, CKD is the most prevalent risk factor for severe COVID-19 worldwide7 (Fig. 1A). Additionally, CKD is the coexistent condition that most increased the risk of COVID-19 death.8 OpenSAFELY analyzed data from 17,278,392 adults and 10,926 COVID19-related deaths in England. In a fully adjusted model, patients cared for by nephrologists, such as dialysis patients (Adj HR 3.69), transplant recipients (Adj HR 3.55) and CKD (Adj HR 2.52 for patients with eGFR<30ml/min/1.73m2, GFR category G4-5) patients were among the top 4 risk categories (Fig. 1B).8 However, within the dialysis/transplant populations (kidney replacement therapy, KRT), the additional risk associated to classical risk factors differs from the general population. Thus, male sex or coexistent diabetes, hypertension, coronary artery disease or lung disease do not further increase the risk of COVID-19 death,9 contrary to observations in persons not on KRT.8 Furthermore, the adverse impact of older age is smaller in persons on KRT: older KRT patients have a ∼4-fold increase in risk vs those in their fifties, as opposed to a ∼15-fold increase in the general population.6 In the early pandemic waves in the most affected countries or cities, such as Madrid, a 30% mortality was reported in dialysis patients.10 This soon decreased to 13–16%, as it became apparent that, as for other populations, there was also a high prevalence of asymptomatic COVID-19 among hemodialysis (HD) patients.11,12 Despite this, mortality remained above that of the general population and had a dramatic impact on the epidemiology of KRT. As an example, in Madrid in 2020, KRT incidence decreased 12% versus 2019 while KRT prevalence decreased (−1.75%) for the first time since records began. COVID-19 was the most common cause of death in 2020 (33% of all deaths) and singlehandedly increased the annual mortality of KRT patients to 10.2% (34% higher than the mean for 2008–2019), more so in kidney transplant recipients (+68%). However, the bulk of COVID-19 deaths (209/285, 73%) occurred during the first COVID-19 wave, which roughly accounted for all the excess mortality of KRT patients in 2020. This temporal pattern of COVID-19 mortality, despite further larger COVID-19 waves observed before vaccines became available, suggests that appropriate healthcare may improve COVID-19 outcomes in KRT patients.13,14

Fig. 1.

Global prevalence of CKD and impact of CKD on COVID-19 mortality. (A) Global prevalence of CKD by age according to Global Burden of Disease (GBD) data. Gray lines represent individual countries. (B) According to these data, CKD accounts for the increased risk of severe COVID-19 in 5.1% of the global population, or 23% of the global population at increased risk of severe COVID-19, as represented in panel B, being the highest contributor to global risk. Data for (A) and (B) from Ref. 7. (C) Risk of COVID-19 death for selected preexistent conditions from Ref 8. Dialysis and transplantation were the conditions that most increased the risk of death from COVID-19 in the OpenSAFELY study. Additionally, the increased risk conveyed by CKD G4/G5 was still higher than that conveyed by several of the often-cited risk factors for severe CVOD-19, including diabetes, chronic heart disease and hypertension. Even CKD G3 conveyed a higher risk of COVID-19 death than heart disease or hypertension. The discontinuous horizontal blue line indicates neutral risk (Adj HR=1.0).

(0.12MB).

Several factors may account for the high impact of COVID-19 on KRT patients, especially during the first wave. Some of them may have been transient, thus contributing to the severe impact of the first COVID-19 wave while others may be permanent, accounting for a persistent increased risk of severe COVID-19. Thus, HD patients were unable to shield, as they had to travel to dialysis facilities thrice weekly. In Spain this entailed shared vehicles with other patients at a time when health authorities were actively suppressing masking.15,16 In this regard, shared transport emerged as a key risk factor for COVID-19.17 Moreover, at a time of severe constraints in access to ICU care, KRT patients may have been considered to have too low chances of survival, in a self-fulfilling prophecy. Finally, early therapy for COVID-19 was not evidence-based, and some of the useless medication combinations used may have increased the risk of fatal arrhythmia associated with long QT in dialysis patients.18 Among more permanent factors, we find the spontaneous immune suppression of uremia, the immunosuppressants prescribed to kidney transplant (KT) recipients and the high prevalence of frailty among KRT patients.

The development of SARS-CoV-2 vaccines opened a new era in the COVID-19 pandemic. Phase III pivotal studies for assessing safety and efficacy of the different vaccines demonstrated protection against severe COVID-19.19–22 Indeed, vaccination was associated to lower rates of admissions and complications derived from SARS-CoV-2 infections, including mortality, for at least 5 months after the initial schedule.23,24 However, and beyond the pivotal clinical trials, a very low number of patients included in prospective studies presented CKD at baseline.25

With this background, we designed the SENCOVAC study with the aim of evaluating humoral response to SARS-CoV-2 vaccines in the CKD spectrum (i.e. patients with advanced CKD [eGFR<30ml/min/1.73m2, peritoneal dialysis [PD], HD and KT recipients).26 This real-world study had a prospective and observational design and included more than fifty centers in Spain. Inclusion and exclusion criteria are summarized in Fig. 2. At baseline, investigators collected epidemiological data, comorbidities, long-term treatments, and data specific for each cohort (Kt/Vurea, dialysis vintage, technique and vascular access for HD and PD patients; immunosuppressive therapy for KT; eGFR for ND-CKD and KT recipients).

Fig. 2.

Design of the SENCOVAC study. Abbreviations: CKD: chronic kidney disease, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration, eGFR: estimated glomerular filtration rate, HD: hemodialysis, PD: peritoneal dialysis, KT: kidney transplant.

(0.28MB).

Following the study protocol, at baseline, 28 days, 3 months, 6 months, and 12 months after completing the initial vaccine schedule, serum samples were obtained and sent to a central laboratory to determine anti-Spike antibodies (Fig. 3). All samples were tested by a CE-marked commercial method, a quantitative chemiluminescence immunoassay (CLIA, Covid-19 Spike Quantitative Virclia® IgG Monotest, Vircell SL, Spain), with a sensitivity and specificity of 96% and 100% respectively that detects IgG antibodies against the SARS-CoV-2 Spike protein. This assay was calibrated against the First WHO International Standard for anti-SARS-CoV-2 human immunoglobulin (NIBSC code: 20/136) and results were expressed as IU/ml. According to the performance studies of the manufacturer, based on the analysis of prepandemic serum samples, values ≤32IU/ml were considered as negative, between 32 and 36IU/ml as equivocal and values >36IU/ml as positive, reflecting the presence of anti-Spike IgG antibodies as a consequence of either previous infection or vaccination. Investigators included an addendum to perform an interim analysis at 9 months only in patients on HD.27

Fig. 3.

Flow chart of the different humoral response assessment in SENCOVAC. Abbreviations: ND-CKD: non-dialysis chronic kidney disease, HD: hemodialysis, PD: peritoneal dialysis, KT: kidney transplant.

(0.56MB).

During the study, some patients received a third and a fourth dose of vaccine. Although initial vaccination was based on BNT162b2 (Pfizer-BioNTech®), mRNA-1273 (Moderna®), ChAdOx1-S (AstraZeneca®) or Ad26.COV.2 (Janssen®) vaccines, subsequent boosters consisted of mRNA-based vaccines (BNT162b2 and mRNA-1273) (Fig. 3). Vaccination schedules were determined by the local public health authorities and investigators did not intervene in vaccine prescription.

The primary objective of the study was to determine the humoral response after SARS-CoV-2 vaccination (initial and boosters) in patients with advance CKD (GFR<30ml/min/1.73m2, HD, DP and KT recipients). Secondary objectives included safety, quantification of anti-Spike antibodies after vaccination, predictors of humoral responses and establishment of cut-off anti-Spike antibody titers for protection against severe breakthrough infections.

Safety and humoral response after SARS-CoV-2 vaccination

The safety and humoral response after SARS-CoV-2 vaccination were evaluated after the initial vaccination schedule, after the third dose and after the fourth dose. Since the timing of sampling was pre-specified, at each time point patients that had received boosters could be compared with those who had not yet received the booster.

Initial vaccination schedule response

SARS-CoV-2 vaccination in patients of the CKD spectrum was safe, with a high incidence of adverse events (>50%) but all of them not serious (i.e., local pain, general discomfort, asthenia). The second dose (in patients with a two-dose scheme, i.e., BNT162b2, mRNA-1273, ChAdOx1-S) generated more adverse events than the first one. Factors associated to local and systemic reactions included previous COVID-19 (before vaccination), being younger or a KT recipient.26

After completing the initial vaccination schedule, patients with CKD presented disparities in their humoral response. The first interim analysis of SENCOVAC included 1746 patients and analyzed humoral response 28 days after vaccination in 301 participants (28 non-dialysis CKD patients, 43 KT recipients, 52 PD and 178 HD patients).26 Anti-Spike antibodies were positive in 95% of the patients (Fig. 4). However, a negative humoral response was detected in 21% of the KT recipients, showing that this population developed suboptimal responses and should be considered at very high-risk of SARS-CoV-2 infections and of complications due to SARS-CoV-2.26 Beyond the risk of KT recipients for a suboptimal humoral response, the type of vaccine was also an independent predictor for humoral response. Specifically, the BNT162b2 (30μcg) vaccine was associated to 6-fold risk for negative humoral response than mRNA-1273 (100μcg), probably due to the different amount of vaccine in each dose.

Fig. 4.

Positive humoral response in each assessment of the SENCOVAC study across all the categories of the CKD spectrum from ref 26,27,38,42,55, 59. Positive immune response was defined as anti-Spike antibody titers above 36IU/ml as positive, while ≤32IU/ml were considered as negative, and between 32 and 36IU/ml as equivocal, based on the manufacturer evaluation of serum from exposed and non-exposed individuals. Abbreviations: ND-CKD: non-dialysis chronic kidney disease, HD: hemodialysis, PD: peritoneal dialysis, KT: kidney transplant.

(0.26MB).

These results agree with other studies recently summarized by Ma BM et al. in a meta-analysis.28 Beyond the lower rates of positive humoral response after initial vaccination of KT recipients compared to other patients with CKD, all the CKD spectrum developed suboptimal humoral responses when compared to healthy controls.28,29 The inherent immunosuppressive state of patients with CKD and specific features of dialysis and KT (immunosuppression, comorbidities) could explain why these cohorts are not fully protected after vaccination.30

The majority of published studies assessing the humoral response to SARS-CoV-2 vaccines in CKD have been based on mRNA vaccines.31 Small reports on vaccines based on other technologies (such as inactivated virus or viral vectors) demonstrated a minimal disadvantage of these vaccines compared to mRNA-based vaccines in the immediate seroconversion in CKD (especially in KT) patients.32–34 On the other hand, and although heterologous regimens (i.e., the use of different types of vaccines) as initial regimens had been poorly explored, at least one study showed their efficacy in enhancing humoral responses over homologous regimens in HD.35

Third dose response

The suboptimal immunization after the initial vaccination schedule was of special importance in vulnerable populations, including patients with CKD. Loss of acquired humoral response was a key point during the pandemic as anti-Spike antibody titers correlated to efficacy.36 In the CKD spectrum, 25% of patients had fully lost their immunity at 3 months with the majority of them presenting significant declines in anti-Spike antibody titers.37 Within the CKD spectrum, KT recipients achieved the higher rates of lost humoral responses, with more than 50% of the fully vaccinated patients having undetectable antibodies (Fig. 4).38 This waning dynamic was more pronounced at 6 months and affected all the CKD spectrum. This situation opened a new scenario: when to administer a new dose of SARS-CoV-2 vaccine.39,40 However, not all patients shared the same temporal pattern of the humoral immune response. Some factors predicted the loss of anti-Spike antibodies such as being a KT recipient, previous lower anti-Spike antibody titers (due to suboptimal response to vaccination or lack of prior SARS-CoV-2 infection) or the type of vaccine.38,39,41 With this background, Spanish health authorities (and other governments worldwide) decided to administrate an early booster dose of mRNA-vaccines, prioritizing vulnerable cohorts (such as CKD patients) and irrespective of the humoral situation.

The 6-month assessment of SENCOVAC included patients who had received 2 or 3 SARS-CoV-2 vaccine doses and allowed to evaluate the response to the third dose in CKD patients42 (Fig. 3). The administration of mRNA-based third doses seroconverted 69% of the previous negative patients. By groups, receiving the third dose was associated to higher proportion of positive humoral response (in comparison to 2 doses) in KT recipients (80% vs. 53%), patients on PD (100% vs. 71%), patients on HD (96% vs. 64%) and patients with ND-CKD (97% vs. 73%) (Fig. 4).42 According to these results and in agreement to other published studies, KT recipients remained as the low-protected cohort even after three vaccine doses.43 In addition to the impaired immunity of KT recipients, the emergence of new SARS-CoV-2 variants may have influenced the capacity of vaccines to elicit anti-SARS-CoV-2 neutralizing antibodies. Al Jurdi et al. conducted a small but elegant study in KT recipients that compared the neutralizing effect across different SARS-CoV-2 variants. They concluded that the third dose of SARS-CoV-2 mRNA vaccines presented lower effectivity against new SARS-CoV-2 variants (i.e., Omicron) than against the original virus.44

In contrast to the results in KT recipients, a robust humoral response was developed by the vast majority (more than 95%) of non-KT recipients that had received the booster.42,45 Although patients with CKD usually received mRNA-based vaccines, some studies explored heterologous regimens with controversial results. Despite the use of mixed vaccine types, altogether studies revealed a humoral benefit with heterologous regimens46–48 constituting an alternative for patients at high risk for low humoral response. A recently published clinical trial assessed the efficacy of a heterologous regimen (ChAdOx1 nCoV-19) vs an mRNA booster (BNT162b2 or mRNA-1273) in immunosuppressed patients who failed to respond to the initial schedule. This study demonstrated the beneficial effect of a homologous mRNA-based regimen.49 By contrast, a randomized clinical trial involving KT recipients with negative humoral response after initial vaccination, demonstrated non-inferiority of a mRNA-based third dose vs a vector-based heterologous vaccination strategy.50

Fourth dose response

Although anti-Spike antibody titers decreased over time, there is scarce information of the fourth dose effect in patients with CKD.51 Published studies have focused their attention to KT recipients, where a fourth dose improves humoral responses, and should be primarily offered to prior non-responders.52–54 In this regard, SENCOVAC showed that in KT recipients the fourth vaccine dose did not significantly increase anti-Spike antibodies titers (Fig. 4). More worrisome was the low rate of seroconversion achieved in previously negative KT recipients after this new booster, raising important concerns over the optimal strategy for persistently negative patients.55 In other CKD cohorts, a humoral response was observed and anti-Spike antibody titers increased after the fourth dose.55,56 In fact, among non-KT recipients, after the third dose, the prevalence of a negative humoral response was very low (<5%).55 Beyond booster administration and prior response to vaccination, steroids and mycophenolate mofetil prescription was associated to low response to a fourth vaccine dose in KT.55,56 Similarly, suboptimal responses to SARS-CoV-2 vaccines were observed in other immunosuppressed populations.57,58 However, whether anti-Spike antibody titers represent the best readout to evaluate an optimal humoral response is unclear and to our knowledge an optimal antibody titer threshold that avoids severe COVID-19 or complications has not yet been identified. Until now, all patients with CKD have been eligible for a full immunization against SARS-CoV-2 with four doses, but the optimal moment for further re-boostering needs to be established.59

A recent report from the general population in Israel disclosed that a fourth dose results in a transient increase in anti-Spike antibody titers and in increased protection from breakthrough COVID-19 for less than three months.60 This suggest that every effort should be made to time booster doses just before COVID-19 waves.

Breakthrough SARS-CoV-2 infections

Protection against severe SARS-CoV-2 infections following vaccination was demonstrated by pivotal clinical trials. The severity of COVID-19 substantially decreased after completing the initial vaccination schedule.61–63 However, vaccination did not reduce to zero the risk of COVID-19 complications and mortality still remained high, especially in KT recipients, despite new SARS-CoV-2 variants that appear be less lethal, at least in populations with a high degree of exposure to SARS-CoV-2 infection and vaccines, the availability of booster doses and increased access to intensive care unit care.64 Data of the last SENCOVAC report shows that probably patients with CKD should benefit from establishing a higher cut-off of anti-Spike antibody titers to ensure their protection, at least against COVID-19 requiring admissions.55 Indeed, we know that the optimal vaccination strategy should consider the infection background, comorbidities, immunosuppressive drugs and the amount of received vaccine (number of doses and type). Luckily, the pandemic is evolving, and we are now facing the same pathogen but with a different costume.

Vaccination against SARS-CoV-2, availability of health care resources, advances in treatment and the evolving virus have changed the impact of COVID-19 on patients with CKD. Initial vaccination and booster doses generate suboptimal humoral and cellular responses in patients with CKD, especially in KT recipients. Future strategies should include the administration of updated vaccines (for emerging SARS-CoV-2 variants) in combination with the use of neutralizing human monoclonal antibodies for high-risk patients and effective antiviral agents that can be prescribed to patients with advanced CKD. Although the protective titer of antibodies has not been established in CKD, stratification of the risk for COVID-19 complications should be based on comorbidities, prescribed treatments and humoral response to prior vaccination.

The present project has been supported by Diaverum, Vifor Pharma, Vircell, Fundación Renal Iñigo Álvarez de Toledo and Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union – NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR), FEDER funds.

B. Quiroga has received honoraria for conferences, consulting fees and advisory boards from Vifor-Pharma, Astellas, Amgen, Bial, Ferrer, Novartis, AstraZeneca, Sandoz, Laboratorios Bial, Esteve, Sanofi-Genzyme, Otsuka. MJ. Soler reports honorarium for conferences, consulting fees and advisory boards from Astra Zeneca, NovoNordsik, Esteve, Vifor, Bayer, Mundipharma, Ingelheim Lilly, Jansen, ICU Medical, and Boehringer. A. Ortiz has received consultancy or speaker fees or travel support from Astellas, Astrazeneca, Amicus, Amgen, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Otsuka and Vifor Fresenius Medical Care Renal Pharma and is Director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra Astrazeneca-UAM of chronic kidney disease and electrolytes. P. de Sequera reports honorarium for conferences, consulting fees and advisory boards from Amgen, Astellas, Astra Zeneca, Baxter, Braun, Fresenius Medical Care, GlaxoSmithKline, Nipro, Otsuka, Sandoz, Nipro, Vifor-Pharma. She is the present president of the Spanish Society of Nephrology (S.E.N.).